Influenza virus polymerase inhibitors in clinical development (Q63976719)

1 July 2020

27 October 2020

22 August 2022

Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site

23 October 2022

cites work

1 reference

12 December 2020

The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit

1 reference

12 December 2020

Use of ribavirin to treat influenza

1 reference

12 December 2020

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

1 reference

12 December 2020

T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro

1 reference

12 December 2020

Characterization of H7N9 influenza A viruses isolated from humans.

1 reference

12 December 2020

Viral RNA polymerase: a promising antiviral target for influenza A virus

1 reference

12 December 2020

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

1 reference

12 December 2020

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2

1 reference

12 December 2020

Characterization of susceptibility variants of influenza virus grown in the presence of T-705.

1 reference

12 December 2020

Structure of influenza A polymerase bound to the viral RNA promoter

1 reference

12 December 2020

Structural insight into cap-snatching and RNA synthesis by influenza polymerase

1 reference

12 December 2020

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit

1 reference

12 December 2020

Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen

1 reference

12 December 2020

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

1 reference

12 December 2020

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

1 reference

12 December 2020

Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice

1 reference

12 December 2020

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir

1 reference

12 December 2020

An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy

1 reference

12 December 2020

The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design

1 reference

12 December 2020

Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice

1 reference

12 December 2020

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

1 reference

12 December 2020

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

1 reference

12 December 2020

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference

1 reference

12 December 2020

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

1 reference

12 December 2020

Combination Therapy with Neuraminidase and Polymerase Inhibitors in Nude Mice Infected with Influenza Virus

1 reference

12 December 2020

JNJ-63623872 treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors.

1 reference

12 December 2020

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in heal

1 reference

12 December 2020

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

1 reference

12 December 2020

Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects

1 reference

12 December 2020

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings

1 reference

12 December 2020

In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit

1 reference

12 December 2020

The mechanism of resistance to favipiravir in influenza

1 reference

12 December 2020

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

1 reference

12 December 2020

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

1 reference

12 December 2020